Inozyme Pharma, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -5.16 | -100% |
| P/S |
|
0 | 33.77 | -100% |
|
|
| P/BV |
|
1.64 | 4.83 | -65.99% |
|
|
| P/FCF |
|
-4.15 | 61 | -106.8% |
|
|
| Ev/Ebitda |
|
-3.26 | -22.17 | -85.28% |
|
|
| Ev/S |
|
0 | 22.57 | -100% |
|
|
| Ev/FCF |
|
-3.42 | 68.76 | -104.97% |
|
|
| E/P |
|
-0.2417 | 0.0178 | -1459.88% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.97 | -100% | 0 | 0% |
| ROE |
|
-50.66 | 9.61 | -627.09% |
|
|
| ROA |
|
-35.43 | 0.3443 | -10392.94% |
|
|
| ROIC |
|
-50.1 | 7.63 | -756.24% |
|
|
| ROS |
|
0 | -25.17 | -100% |
|
|
| ROCE |
|
-53.85 | 15.45 | -448.54% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.6144 | -3.68 | -83.29% | -0.4023 | +52.71% |
| Nеt Debt/Ebitda |
|
-0.1615 | -3.44 | -95.3% |
|
|
| Debt/Ratio |
|
0.2274 | 0.1986 | 14.53% |
|
|
| Debt/Equity |
|
22.84 | 1.66 | 1273.92% |
|
|
| Debt/Net Income |
|
-0.6418 | 10.32 | -106.22% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.541 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2256 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9598 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4928 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.541 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | -57.64 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
261.41 | -90.94 | -387.45% | ||
| Growth impulse Net Income in 5 years |
|
255.85 | -97.8 | -361.61% | ||
| Growth impulse FCF in 5 years |
|
273.54 | -108.72 | -351.6% | ||
| Growth impulse EPS in 5 years |
|
5.61 | -142.05 | -103.95% |
IP Score
3.54/10
